Retina

At ARVO 2025, in Salt Lake City, Utah, Emma Lessieur-Contreras, MD, PhD, talked about her poster on retina extracellular vesicles, and the role that they play on diabetic retinopathy.

Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease.

Lori Wright, JD, sat down to talk about a discussion at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.

Dilraj S. Grewal, MD, FASRS, provides an in-depth overview of the current state of research and treatment innovations.

This partnership aims to address care gaps by identifying untreated and undertreated patients at scale.

Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections caused by povidone iodine.

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of 2 tissue patches in immediate succession while minimizing damage to the surrounding tissue.

ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

At ARVO 2025, in Salt Lake City, Utah, Steven Barnes, PhD, talked about his research on the OPA1 mutation in retinal ganglion cells' effect on the cell's electrical function.

Swedish researchers reveal that vitamins B6, B9, B12, and choline offer neuroprotection against glaucoma, highlighting potential new treatment avenues.

At ARVO 2025, in Salt Lake City, Utah, Alex Choi discussed his poster on APOE carrier genetic status and its relation to Alzheimer disease as well as changes of the retina that might reflect early signs leading to an earlier diagnosis of the disease

At ARVO 2025, in Salt Lake City, Utah, Yuhua Zhang, PhD, talked about his presentation on in vivo imaging of retinal pigment epithelium metabolic function in age-related macular degeneration

At ARVO 2025, in Salt Lake City, Utah, Xiaolin Wang, MS, talked about her presentation on in vivo imaging of retinal pigment epithelium metabolic function in AMD.

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

At ARVO 2025, in Salt Lake City, Utah, David Almeida, MD, MBA, PhD, talked about 12-month results from the PAVIA phase 2 trial of EYP-1901 in nonproliferative diabetic retinopathy.

Kapil Mishra, MD, discusses his presentation title "Radiation Retinopathy: Future Strategies" given at the 2025 Retina World Congress meeting.

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

By making these retinal pigment epithelium (RPE) cells visible, researchers have created implications for early detection of disease and the monitoring of treatment response.

At ARVO 2025, in Salt Lake City, Utah, C Michael Samson, MD, MBA, gave insight into his data on immune cell profiling in birdshot retinochoroidopathy using single-cell RNA sequencing.

AAVantgarde Bio reveals promising safety and efficacy data for AAV-based therapies targeting Usher syndrome and Stargardt disease at ARVO 2025.